secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001437749-25-007032
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics reports FY 2024 net loss of $105.5M; sells PRV for $150M, cash runway into 2029
--------------------------------------------------------------------------------

- FY 2024 net revenue $23.6M (record Q4 product revenue $10.2M from MIPLYFFA); net loss ($105.5M) vs ($46.0M) in 2023.
- Entered asset purchase agreement to sell Rare Pediatric Disease PRV for $150M gross; expected net proceeds $148.3M.
- Cash and investments $75.5M at Dec 31, 2024; with PRV sale, cash runway extends into 2029; no going concern disclosure.
- MIPLYFFA commercial launch: 109 total prescription enrollment forms as of Dec 31; EU filing targeted H2 2025.
- OLPRUVA added 4 new patients Q4; DiSCOVER trial (VEDS) enrolled 27 patients; strategic review for KP1077 ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774925007032/0001437749-25-007032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774925007032/zvra20240918_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-007032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer